Tech Center 1600 • Art Units: 1632
This examiner grants 25% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17914246 | ENTERIC NITRERGIC NEURONS AND METHODS OF USING THE SAME | Non-Final OA | The Regents of the University of California |
| 18012959 | METHOD FOR PREPARING COMPOSITION FOR CULTURING PANCREATIC ORGANOIDS, COMPOSITION THEREFOR, AND METHOD FOR CULTURING ORGANOIDS BY USING SAME | Non-Final OA | POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION |
| 18176959 | PRODUCTION METHOD FOR MICROGLIA | Final Rejection | RICOH COMPANY, LTD. |
| 17189376 | NUCLEIC ACID DELIVERY CARRIER, NUCLEIC ACID DELIVERY CARRIER SET, NUCLEIC ACID DELIVERY COMPOSITION, AND NUCLEIC ACID DELIVERY METHOD | Non-Final OA | KABUSHIKI KAISHA TOSHIBA |
| 17772539 | PROTEASE SWITCH FOR DUAL TARGETS CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | Non-Final OA | THE TEXAS A&M UNIVERSITY SYSTEM |
| 17044779 | NANOPARTICLES FOR GENE EXPRESSION AND USES THEREOF | Non-Final OA | Fred Hutchinson Cancer Center |
| 17965656 | COMPOSITIONS FOR PREVENTING OR TREATING DIABETIC SKIN DISEASE COMPRISING EXOSOME-DERIVED FROM THROMBIN-TREATED STEM CELL | Non-Final OA | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION |
| 17429215 | PHARMACEUTICAL COMPOSITION FOR PREVENTING IN-STENT RESTENOSIS | Non-Final OA | Nipro Corporation |
| 17421908 | COMPOSITIONS AND METHODS FOR TREATMENT OF A MALABSORPTIVE DISORDER | Final Rejection | CHILDREN'S HOSPITAL MEDICAL CENTER |
| 17435943 | CULTURE MEDIUM FOR MAMMALIAN EXPANDED POTENTIAL STEM CELLS, COMPOSITION, AND METHODS THEREOF | Final Rejection | THE UNIVERSITY OF HONG KONG |
| 18043507 | METHOD OF PRODUCING THREE-DIMENSIONAL TISSUE BODY AND THREE-DIMENSIONAL TISSUE BODY | Non-Final OA | OSAKA UNIVERSITY |
| 17251587 | USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING | Non-Final OA | Figene, LLC |
| 17461094 | USE OF ENDOTHELIAL PROGENITOR CELLS IN REJUVENATING THE MICROVASCULATURE, PREVENTING AGING AND TREATING AGE-RELATED DISEASES | Non-Final OA | SHENZHEN UNIVERSITY |
| 17582609 | Methods of Cell Renewal | Non-Final OA | CarryGenes Bioengineering, LLC |
| 17761677 | GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRYTHMOGENIC CARDIOMYOPATHY | Non-Final OA | UCL BUSINESS LTD |
| 17418203 | METHOD FOR INDUCING MUSCULAR CELLS USING CELLS IN SPOT URINE | Final Rejection | NIPPON SHINYAKU CO., LTD. |
| 18183900 | THERAPEUTIC REGENERATIVE CELLS | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 17143795 | MICROFABRICATED DEVICES AND HIGH THROUGHPUT ASSAYS FOR MODULATORS OF CELL BEHAVIOR | Final Rejection | NOVOHEART INTERNATIONAL LIMITED |
| 18130555 | HUMAN UMBILICAL CORD COMPOSITION FOR TREATMENT OF PEYRONIE'S DISEASE | Final Rejection | BioStem Technologies, Inc. |
| 18044061 | METHOD FOR DIFFERENTIATING CORNEAL ENDOTHELIAL CELL-LIKE CELLS FROM PLURIPOTENT STEM CELLS | Final Rejection | StemSight Oy |
| 18174853 | METHOD FOR PRODUCING CARTILAGE CELLS INDUCED TO BE DIFFERENTIATED FROM STEM CELLS | Non-Final OA | YiPCELL Inc. |
| 17985365 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | Non-Final OA | Stellular Bio, Inc. |
| 17423044 | A NOVEL CD16+ NATURAL KILLER CELL AND A METHOD OF CULTURING CD16+ NATURAL KILLER CELL | Non-Final OA | Acepodia Biotechnologies Ltd. |
| 17775106 | PRIMARY BREAST EPITHELIAL CELL CULTURE MEDIUM, CULTURE METHOD AND USE THEREOF | Non-Final OA | PRECEDO PHARMACEUTICALS CO., LTD |
| 17771431 | METHODS AND APPARATUS FOR MEASURING IMMUNE MEDIATED TUMOROID RESPONSES | Non-Final OA | VITROSCAN B.V. |
| 17430652 | Use of Haploid Embryonic Cells to Generate Offspring with Predetermined Genomes | Non-Final OA | UNIVERSITÉ DE MONTRÉAL |
| 17543911 | COMPOSITION FOR TREATING INFLAMMATORY DISEASE INDUCED BY HYPERIMMUNE RESPONSE | Final Rejection | KOLON TISSUEGENE, INC. |
| 17602936 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTICS | Non-Final OA | Encoded Therapeutics, Inc. |
| 17430623 | CRYOPRESERVATION OF STEM CELLS | Non-Final OA | TiGenix, S.A.U. |
| 17260545 | CRYOPRESERVATION | Non-Final OA | NantKwest, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy